Lexaria Bioscience (LEXX) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Lexaria Bioscience has announced preliminary findings from its second human pilot study, indicating that its DehydraTECH-processed Rybelsus medication may enhance overall absorption when taken with food. Although the sample size was small and results were not statistically significant, there was an average 18.8% increase in semaglutide levels over the course of the study compared to the non-processed version. The study compared the absorption of the drug in tablet and capsule forms when taken in a fed state, against the manufacturer’s recommendation of administration on an empty stomach.
For further insights into LEXX stock, check out TipRanks’ Stock Analysis page.